Lundbeck is tapping into the brain-drug delivery expertise of Netherlands-based to-BBB through a collaboration focused on delivering antibodies against central nervous system diseases. The research will focus on the use of to-BBB's G-Technology, which uses liposomes coated with glutathione-conjugated PEG to mediate the safe targeting and enhanced delivery of drugs directly across the blood-brain barrier.
The collaboration with Lundbeck is the fourth for to-BBB within the last few months. In November the company signed a research collaboration with Genzyme to evaluate the use of the G-Technology as a delivery vehicle for biologics against neurodegenerative diseases.
In September to-BBB teamed up with MedImmune to investigate the safe delivery of drugs to the brain using the G-Technology. In June the company announced a collaboration with researchers at The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) focused on developing a potential new therapy for brain tumors.
To-BBB's lead in-house candidate is G-Technology formulated doxorubicin, 2B3-101, which is expected to start clinical trials during the second half of 2010.